Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48

Article  PubMed  Google Scholar 

Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13(6):1010–1021

Article  PubMed  Google Scholar 

Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M et al (2022) Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(10):992–1004

Article  PubMed  Google Scholar 

Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB et al (2023) Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol 41(7):1470–1491

Article  CAS  PubMed  Google Scholar 

Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A et al (2020) Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol 11(2):55–64

Article  PubMed  PubMed Central  Google Scholar 

Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C et al (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 67(6):622–628

Article  PubMed  Google Scholar 

Khan MS, Ochani RK, Shaikh A, Usman MS, Yamani N, Khan SU et al (2019) Fragility index in cardiovascular randomized controlled trials. Circ Cardiovasc Qual Outcomes 12(12):e005755

Article  PubMed  PubMed Central  Google Scholar 

Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G (2016) The fragility index in multicenter randomized controlled critical care trials. Crit Care Med 44(7):1278–1284

Article  PubMed  Google Scholar 

Desnoyers A, Nadler MB, Saleh R, Amir E (2020) Abstract P4–15-01: fragility index of trials supporting approval of breast cancer drugs. Cancer Res 80(4_Supplement):P4–P15

Article  Google Scholar 

Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N et al (2023) Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022). JHEP Rep 5(7):100755

Article  PubMed  PubMed Central  Google Scholar 

Horesh N, Bomze D, Lim C, Markel G, Meirson T, Azoulay D (2022) Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect. Hepatobiliary Surg Nutr 11(6):861–869

Article  PubMed  PubMed Central  Google Scholar 

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71

Article  Google Scholar 

Fragility Index Calculator [Internet]. Available from: https://clincalc.com/Stats/FragilityIndex.aspx. Accessed 13 Dec 2023

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458

Article  CAS  PubMed  Google Scholar 

Ni W, Yu S, Xiao Z, Zhou Z, Chen D, Feng Q et al (2021) Postoperative adjuvant therapy versus surgery alone for stage IIB-III esophageal squamous cell carcinoma: a phase III randomized controlled trial. Oncologist 26(12):e2151–e2160

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tachibana M, Yoshimura H, Kinugasa S, Shibakita M, Dhar DK, Ueda S et al (2003) Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol 29(7):580–587

Article  CAS  PubMed  Google Scholar 

Conroy T, Galais M-P, Raoul J-L, Bouché O, Gourgou-Bourgade S, Douillard J-Y et al (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15(3):305–314

Article  CAS  PubMed  Google Scholar 

Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y et al (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106(4):407–412

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teoh AYB, Chiu PWY, Yeung WK, Liu SYW, Wong SKH, Ng EKW (2013) Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 24(1):165–171

Article  CAS  PubMed  Google Scholar 

Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P et al (2021) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol 39(18):1995–2004

Article  CAS  PubMed  Google Scholar 

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z et al (2021) Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg 156(8):721–729

Article  PubMed  PubMed Central  Google Scholar 

Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N et al (2006) Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus 19(6):468–472

Article  CAS  PubMed  Google Scholar 

Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH et al (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15(6):947–954

Article  CAS  PubMed  Google Scholar 

Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26(7):1086–1092

Article  CAS  PubMed  Google Scholar 

Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 32(23):2416–2422

Article  CAS  PubMed  Google Scholar 

Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19(2):305–313

Article  CAS  PubMed  Google Scholar 

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27(30):5062–5067

Article  PubMed  Google Scholar 

Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359(9319):1727–1733

Article  Google Scholar 

Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ et al (2011) Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 19(11):181

Article  Google Scholar 

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68–74

Article  PubMed  Google Scholar 

Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG et al (2022) Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol 23(2):259–269

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A et al (2018) Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 29(6):1386–1393